Cargando…

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

OBJECTIVE: Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This article provides an overview of efficacy and safety information for duloxetine 60 mg/day in the treatment of MDD, including its effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ball, Susan G, Desaiah, Durisala, Zhang, Qi, Thase, Michael E, Perahia, David G S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Just Medical Media Limited 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884746/ https://www.ncbi.nlm.nih.gov/pubmed/24432034 http://dx.doi.org/10.7573/dic.212245

Ejemplares similares

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
por: Skljarevski, Vladimir, et al.
Publicado: (2012)

Duloxetine in the treatment of major depressive disorder: an open-label study
por: Hudson, James I, et al.
Publicado: (2007)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
por: Fornaro, Michele, et al.
Publicado: (2011)

Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: post hoc analysis of a cross-sectional study
por: Romera, Irene, et al.
Publicado: (2011)

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
por: Babu, P Ravindra, et al.
Publicado: (2017)

Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2011)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
por: Fleischmann, Roy, et al.
Publicado: (2008)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
por: Park, Young-Min, et al.
Publicado: (2010)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
por: Ye, Wenyu, et al.
Publicado: (2011)

Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials
por: Alev, Levent, et al.
Publicado: (2017)

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
por: Fu, Cynthia HY, et al.
Publicado: (2015)

Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study
por: Yasuda, Hitoshi, et al.
Publicado: (2015)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
por: Mallinckrodt, Craig H, et al.
Publicado: (2005)

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
por: Roehrborn, Claus G, et al.
Publicado: (2008)

Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris
por: Pozdnyakov, Yuri M.
Publicado: (2018)

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial
por: Winston, Alan, et al.
Publicado: (2014)

The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder
por: Lee, Min-Soo, et al.
Publicado: (2012)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
por: Sun, Ching-Fang, et al.
Publicado: (2019)

The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents
por: MacDonald, T M, et al.
Publicado: (2010)

Efficacy of twice-daily vs once-daily sessions of repetitive transcranial magnetic stimulation in the treatment of major depressive disorder: a retrospective study
por: Modirrousta, Mandana, et al.
Publicado: (2018)

Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
por: Han, Dan, et al.
Publicado: (2015)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
por: Wohlreich, Madelaine M, et al.
Publicado: (2004)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada, Eiji, et al.
Publicado: (2016)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Depression Treatment with Duloxetine and Reduction of Inability to Work
por: Happich, Michael, et al.
Publicado: (2012)

A Review of Vilazodone, Serotonin, and Major Depressive Disorder
por: Pierz, Kerri A., et al.
Publicado: (2014)

Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database
por: Lin, Nancy D., et al.
Publicado: (2015)

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
por: White, Darrell, et al.
Publicado: (2023)

Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome
por: Benelli, Andrea, et al.
Publicado: (2018)

Daily intake of 30 mg duloxetine is effective in decreasing premature ejaculation severity: a prospective randomized placebo-controlled cross over clinical trial
por: Zaazaa, Adham, et al.
Publicado: (2023)

Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice
por: Glezer, Maria G., et al.
Publicado: (2018)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider, Miqdad, et al.
Publicado: (2017)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l771cd6f8p6gqc1n7pitaplli4